| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
44,360,000 |
| Market
Cap: |
55.89(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.9693 - $2.87 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : 4.5 |
| Insider 6 Months : 4.5 |
| Insider 3/6 Months : 9.3 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Immunic is a clinical-stage biopharmaceutical company. Co. is pursuing three development programs. These include the vidofludimus calcium (IMU-838) program, which is focused on the development of oral formulations of a small molecule inhibitor of the enzyme dihydroorotate dehydrogenase; the IMU-935 program, which is focused on an inverse agonist of retinoic acid receptor-related orphan nuclear receptor gamma truncated, an immune cell-specific isoform of retinoic acid receptor-related orphan nuclear receptor gamma; and the IMU-856 program, which involves the development of a drug targeting the restoration of intestinal barrier function and regeneration of bowel epithelium.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
14,000 |
14,000 |
19,000 |
139,000 |
| Total Buy Value |
$18,333 |
$18,333 |
$27,083 |
$257,547 |
| Total People Bought |
1 |
1 |
2 |
5 |
| Total Buy Transactions |
1 |
1 |
2 |
11 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Vitt Daniel |
President and CEO |
• • – |
2024-02-26 |
4 |
B |
$1.31 |
$18,333 |
I/I |
14,000 |
390,877 |
2.58 |
-2% |
|
| Whaley Glenn |
Chief Financial Officer |
• – – |
2023-05-15 |
4 |
B |
$1.75 |
$8,750 |
D/D |
5,000 |
25,510 |
2.74 |
-23% |
|
| Neermann Joerg |
Director |
– • – |
2022-12-14 |
4 |
B |
$1.26 |
$59,032 |
D/D |
47,000 |
100,000 |
2.39 |
29% |
|
| Neermann Joerg |
Director |
– • – |
2022-12-13 |
4 |
B |
$1.25 |
$43,610 |
D/D |
35,000 |
53,000 |
2.39 |
26% |
|
| Vitt Daniel |
President and CEO |
• • – |
2022-11-22 |
4 |
B |
$1.35 |
$10,799 |
I/I |
8,000 |
376,877 |
2.58 |
14% |
|
| Whaley Glenn |
Chief Financial Officer |
• – – |
2022-11-07 |
4 |
B |
$1.50 |
$7,475 |
D/D |
5,000 |
20,510 |
2.74 |
18% |
|
| Vitt Daniel |
President and CEO |
• • – |
2022-06-03 |
4 |
B |
$3.10 |
$15,500 |
I/I |
5,000 |
368,877 |
2.58 |
219% |
|
| Whaley Glenn |
Chief Financial Officer |
• – – |
2022-06-03 |
4 |
B |
$3.05 |
$10,658 |
D/D |
3,500 |
12,568 |
2.74 |
219% |
|
| Muehler Andreas |
Chief Medical Officer |
• – – |
2022-05-12 |
4 |
B |
$5.10 |
$17,850 |
D/D |
3,500 |
297,986 |
2.74 |
-38% |
|
| Nash Duane |
Executive Chairman |
• • – |
2022-05-12 |
4 |
GD |
$0.00 |
$0 |
D/D |
6,000 |
16,032 |
|
- |
|
| Nash Duane |
Executive Chairman |
• • – |
2022-05-12 |
4 |
B |
$5.03 |
$50,300 |
D/D |
10,000 |
22,032 |
2.81 |
-38% |
|
| Whaley Glenn |
Chief Financial Officer |
• – – |
2022-05-12 |
4 |
B |
$5.08 |
$15,240 |
D/D |
3,000 |
9,068 |
2.74 |
-38% |
|
| Vitt Daniel |
President and CEO |
• • – |
2021-08-10 |
4 |
B |
$9.60 |
$9,600 |
I/I |
1,000 |
363,877 |
2.58 |
-2% |
|
| Whaley Glenn |
PFO and PAO |
• – – |
2021-08-10 |
4 |
B |
$9.85 |
$14,775 |
D/D |
1,500 |
3,500 |
2.74 |
-2% |
|
| Nash Duane |
Executive Chairman |
• • – |
2021-08-10 |
4 |
B |
$9.80 |
$9,800 |
D/D |
1,000 |
15,032 |
2.81 |
-2% |
|
| Nash Duane |
Executive Chairman |
• • – |
2021-05-12 |
4 |
B |
$12.75 |
$51,000 |
D/D |
4,000 |
14,032 |
2.81 |
-29% |
|
| Muehler Andreas |
Chief Medical OfficerOfficer |
• – – |
2021-03-10 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
10,006 |
|
-40% |
|
| Muehler Andreas |
Chief Medical OfficerOfficer |
• – – |
2021-03-10 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
284,480 |
|
-40% |
|
| Muehler Andreas |
Chief Medical Officer |
• – – |
2021-03-02 |
4 |
B |
$15.54 |
$155,493 |
D/D |
10,006 |
294,486 |
2.74 |
-20% |
|
| Whaley Glenn |
PFO and PAO |
• – – |
2021-03-02 |
4 |
B |
$16.48 |
$16,480 |
D/D |
1,000 |
2,000 |
2.74 |
-20% |
|
| Whaley Glenn |
PFO and PAO |
• – – |
2020-08-10 |
4 |
B |
$18.96 |
$18,960 |
D/D |
1,000 |
1,000 |
2.74 |
-10% |
|
| Vitt Daniel |
Chief Executive Officer |
• • – |
2020-07-21 |
4 |
AS |
$15.62 |
$20,310 |
I/I |
(1,300) |
362,877 |
|
6% |
|
| Groeppel Manfred |
Chief Operating Officer |
• – – |
2020-07-21 |
4 |
AS |
$15.62 |
$10,155 |
I/I |
(650) |
278,830 |
|
6% |
|
| Vitt Daniel |
Chief Executive Officer |
• • – |
2020-07-20 |
4 |
AS |
$14.44 |
$72,201 |
I/I |
(5,000) |
364,177 |
|
24% |
|
| Groeppel Manfred |
Chief Operating Officer |
• – – |
2020-07-20 |
4 |
AS |
$14.44 |
$72,201 |
I/I |
(5,000) |
279,480 |
|
24% |
|
87 Records found
|
|
Page 1 of 4 |
|
|
0.03 (2.44%) 
